New hope for kids with tough cancer: drug combo shows promise

NCT ID NCT02914405

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 27 times

Summary

This early-phase study tests a new combination of three drugs (radioactive therapy, an immunotherapy, and a checkpoint inhibitor) in children whose neuroblastoma has come back or not responded to treatment. The main goal is to see if the combination is safe and tolerable. About 44 children across the UK, Germany, and the US will take part. If successful, this approach could lead to better control of this aggressive childhood cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • University College London Hospital

    London, London, NW1 2BU, United Kingdom

  • University Hospital Southampton NHS Foundation Trust

    Southampton, Hampshire, SO16 6YD, United Kingdom

  • University of Wisconsin Carbone Cancer Center; UW Hospital and Clinics; American Family Children's Hospital

    Madison, Wisconsin, 53792, United States

Conditions

Explore the condition pages connected to this study.